Want to see IN:VINEETLAB full AI Analyst Report?
VINEETLAB Stock Chart & Stats
₹40.51
₹2.19(3.77%)
At close: 4:00 PM EST
₹40.51
₹2.19(3.77%)
Day’s Range― - ―
52-Week Range₹24.41 - ₹43.56
Previous CloseN/A
Volume164.54K
Average Volume (3M)6.84K
Market Cap
₹717.16M
Enterprise Value₹749.66M
Total Cash (Recent Filing)₹6.54M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.00
Shares Outstanding19,206,266
10 Day Avg. Volume3,453
30 Day Avg. Volume6,845
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.81
Price to Sales (P/S)0.35
P/FCF Ratio2.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recent Positive Free Cash FlowA return to positive free cash flow in the latest year indicates the company can generate operating cash after investments, reducing dependence on external funding. Sustained FCF supports debt servicing, working-capital needs and potential reinvestment over the next 2–6 months.
Asset Coverage Vs LiabilitiesMaintaining a reasonable asset base relative to liabilities implies some balance-sheet resilience despite leverage. This provides flexibility to manage short-term obligations and supports operational continuity while strategic improvements to margins and cash generation are pursued.
Lower Market VolatilityA beta well below 1 suggests the company’s equity has historically been less sensitive to market swings, which can translate into more stable cash flows and lower financing cost volatility. This stability aids planning and execution of multi-month operational turnarounds.
Bears Say
Steep Revenue DeclineA roughly 44% decline in revenue reflects severe demand or market-share pressures and undermines scale economics. Over several months this compresses margins, reduces cash generation potential, and makes recovery harder without clear demand-restoration initiatives or new revenue streams.
Negative ProfitabilitySustained operating losses and negative margins indicate core operations fail to cover costs, eroding retained earnings and limiting reinvestment. Persistent unprofitability raises structural risks to business continuity unless cost structure or pricing power meaningfully improves.
High LeverageSignificant leverage increases financial risk by elevating fixed servicing costs and reducing flexibility to weather demand shocks. Over the medium term, high debt constrains strategic options, increases refinancing risk and magnifies the impact of any further earnings weakness.
Vineet Laboratories Ltd. News
VINEETLAB FAQ
What was Vineet Laboratories Ltd.’s price range in the past 12 months?
Vineet Laboratories Ltd. lowest stock price was ₹24.41 and its highest was ₹43.56 in the past 12 months.
What is Vineet Laboratories Ltd.’s market cap?
Vineet Laboratories Ltd.’s market cap is ₹717.16M.
When is Vineet Laboratories Ltd.’s upcoming earnings report date?
Vineet Laboratories Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 107 days.
How were Vineet Laboratories Ltd.’s earnings last quarter?
Currently, no data Available
Is Vineet Laboratories Ltd. overvalued?
According to Wall Street analysts Vineet Laboratories Ltd.’s price is currently Overvalued.
Does Vineet Laboratories Ltd. pay dividends?
Vineet Laboratories Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Vineet Laboratories Ltd. dividends here
What is Vineet Laboratories Ltd.’s EPS estimate?
Vineet Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vineet Laboratories Ltd. have?
Vineet Laboratories Ltd. has 19,206,266 shares outstanding.
What happened to Vineet Laboratories Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vineet Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VINEETLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vineet Laboratories Ltd.
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Technical Analysis
Diamines & Chemicals Ltd.
―
DMCC Speciality Chemicals Limited
―
Indo Amines Limited
―
Primo Chemicals Limited
―
Ishan Dyes and Chemicals Limited
―